OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Net Cash Provided by Financing Activities

Last Annual Value

163.00K

3-Year CAGR

-82%

5-Year CAGR

-68%

10-Year CAGR

-43%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Net Cash Provided by Financing Activities

OKUR · NASDAQ
CompanyNet Cash Provided by Financing Activities
CAGR 3Y
CAGR 5Y
CAGR 10Y
163.00K
-85.5%-73.8%N/A 
12.77B
820.5%204.4%106.4%
-10.59M
N/AN/AN/A
101.64M
4.8%5.3%N/A
19.51M
60.8%-18.6%-0.4%
87.78M
N/A-19.6%N/A
29.32M
25.4%-3.6%6.4%
4.09M
-64.9%-42.2%-23.3%
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47